News | November 14, 2024
AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Subscribe To Our Newsletter & Stay Updated
